drugset / Trial / NCT05651516

Tau PET Imaging in Opioid Use Disorder

NCT05651516 ↗

NaSingle-groupOpen-labelDiagnostic

Summary

The investigators plan to enroll up to 60 adult subjects in this study. There will be three groups of up to 20 subjects each in this study. Group 1: individuals with OUD and a history of at least one opioid-related OD in the past 5 years that required naloxone treatment reversal: OUD/OD+ Group 2: individuals with OUD without a lifetime history of opioid-related OD OUD/OD- Group 3: Healthy controls without a lifetime OUD: HCs PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.

Timeline

Start
2023-09-21
Primary completion
2026-06-02
Completion
2026-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]PI-2620 Diagnostic / imaging agent — —